AI-generated · cited to primary sources · not investment advice · How we research
Cipla
Our verdict on Cipla isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The chronic therapy mix in the Indian branded prescription business improved to 61.8% in Q2 FY26, surpassing the previous quarter's level. (3 exceeded across 3 tracked commitments)
“So I think if you look at it, the market grows at about 8% to 9% in the domestic formulation business. So I think we expect that to continue.”
Cipla's North America revenue for Q1 FY26 reached $226 million, surpassing the guided $220 million. (1 exceeded across 1 tracked commitment)
“North America $ 226 Mn”
See the full cited Management analysis of Cipla
How durable is the business?
Cipla is aggressively expanding its complex generic pipeline, specifically in peptides and respiratory assets, to offset the eventual revenue compression from generic Revlimid. (3 expanding)
“In respiratory, we have filed 6 assets... In peptides and complex generics, 9 assets are already filed and some launches projected between FY '26 and '28.”
The One-India business reached a major milestone, surpassing INR 11,000 crores in annual revenue. Growth was driven by branded prescriptions, trade generics, and consumer health, despite seasonal challenges in acute categories. (5 expanding across 1 engine)
“Our One-India business delivered a strong quarter with 10% year-on-year growth, reinforcing its momentum and commitment to sustainable long-term growth.”
See the full cited Business Model analysis of Cipla
Where does growth come from?
Profitability is showing a strong upward trend. EBITDA margins improved from 24.5% in FY24 to 25.9% in FY25. The final quarter (Q4) showed a significant 150 basis point improvement compared to the same period last year, driven by better product mix and operating efficiency. (2 accelerating, 2 steady across 4 signals, 1 leading indicator)
“we entered into a strategic agreement with Pfizer for exclusive marketing and distribution rights of four well-established Pfizer brands in India. We also signed a definitive agreement to acquire Inzpera Health Sciences”
Cipla is actively expanding and de-risking its manufacturing footprint. This includes a recently capitalized China facility and preparing two U.S. facilities to supply respiratory products (MDI/DPI). (1 new trend across 1 signal, 1 leading indicator)
“let's say from 0 to 6 months, we are calling for... two big respiratory launches, and one smaller launch, right, on respiratory... Then we have peptide launches... in the 6 months to 12 months trajectory.”
See the full cited Future Growth analysis of Cipla
What could break the thesis?
The risk remains stable but high; while FY25 EBITDA (25.9%) exceeded guidance, management has lowered the FY26 outlook to 23.5%-24.5% specifically due to the Revlimid revenue cliff. (2 stable, 1 easing, 2 intensifying, 1 high-severity)
“of the 66 million rough decline in the US sales on a sequential basis, how much directionally we can attribute to Revlimid versus Lanreotide? Ashish Adukia: So, a significant portion of that comes from Revlimid, a major portion of that.”
The risk is INTENSIFYING as management lowered the full-year EBITDA margin guidance from 23.5%-24.5% down to 22.75%-24% due to higher R&D and the Revlimid tail-off. (3 intensifying, 2 easing, 1 high-severity)
“The EBITDA margin, excluding other income, stood at 17.7%... The decline in EBITDA margin was primarily driven by lower generic Revlimid revenues... these are deliberate strategic choices and will lead to FY’26 EBITDA margin guidance to land at around 21%.”
See the full cited Risk analysis of Cipla
Read the full thesis on Cipla
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.